[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Spugnini EP, Cardillo I, Verdina A, Crispi S, Saviozzi S, Calogero R, Nebbioso A, Altucci L, Cortese G, Galati R, Chien J, Shridhar V, Vincenzi B, Citro G, Cognetti F, Sacchi A, Baldi A: Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma. Clin Cancer Res; 2006 Oct 15;12(20 Pt 1):6133-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma.
  • PURPOSE: The aim of the present study was to evaluate the effects of piroxicam, a widely used nonsteroidal anti-inflammatory drug, alone and in combination with cisplatin (CDDP), on cell growth of mesothelioma cells.
  • Moreover, the effects of piroxicam and CDDP on tumor growth and survival of mouse xenograft models of mesothelioma were determined.
  • RESULTS: Piroxicam treatment of MSTO-211H and NCI-H2452 cells resulted in a significant inhibition of proliferation.
  • Last, GeneChip array analysis of MSTO-211H mesothelioma cell line revealed that piroxicam treatment caused up-regulation of metabolic pathway-associated genes and down-regulation of genes related to RNA processing apparatus.
  • Of note, epidermal growth factor receptor, one of the new biological targets of chemotherapy for mesothelioma, was down-regulated and HtrA1, a serine protease recently shown to be an endogenous mediator of CDDP cytotoxicity, was up-regulated following piroxicam treatment both in vitro and in vivo.
  • CONCLUSION: These data suggest that piroxicam sensitizes mesothelioma cells to CDDP-induced cytotoxicity by modulating the expression of several target genes.
  • Therefore, piroxicam in combination with CDDP might potentially be useful in the treatment of patients with mesothelioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Mesothelioma / drug therapy. Peritoneal Neoplasms / drug therapy. Piroxicam / therapeutic use
  • [MeSH-minor] Animals. Cell Division / drug effects. Cell Line, Tumor. Cell Survival / drug effects. Disease Models, Animal. Female. Humans. Mice. Mice, Nude

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17062690.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 13T4O6VMAM / Piroxicam; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


2. Catalano A, Graciotti L, Rinaldi L, Raffaelli G, Rodilossi S, Betta P, Gianni W, Amoroso S, Procopio A: Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention. Int J Cancer; 2004 Apr 10;109(3):322-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention.
  • Malignant mesothelioma (MM) remains the most lethal pleural, peritoneal and pericardial cancer.
  • Celecoxib, in a dose- and time-dependent manner, induced MM cell apoptosis, which involved decreased Akt phosphorylation, loss of Bcl-2 and Survivin protein expression and caspase-3 activation.
  • These data demonstrate that celecoxib may have antitumor properties in MM and provide a rationale for the therapeutic use of celecoxib in combination with a selective VEGF inhibitor.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Mesothelioma / drug therapy. Protein-Serine-Threonine Kinases. Proto-Oncogene Proteins / antagonists & inhibitors. Sulfonamides / therapeutic use
  • [MeSH-minor] Animals. Apoptosis. Caspase 3. Caspases / metabolism. Celecoxib. Chemoprevention. Cyclooxygenase Inhibitors / pharmacology. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Phosphorylation / drug effects. Proto-Oncogene Proteins c-akt. Proto-Oncogene Proteins c-bcl-2 / metabolism. Pyrazoles. Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors. Receptors, Vascular Endothelial Growth Factor / metabolism. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. CELECOXIB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 14961568.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Cyclooxygenase Inhibitors; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Pyrazoles; 0 / Sulfonamides; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


3. Vandermeers F, Hubert P, Delvenne P, Mascaux C, Grigoriu B, Burny A, Scherpereel A, Willems L: Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin Cancer Res; 2009 Apr 15;15(8):2818-28
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma.
  • PURPOSE: Present chemotherapeutic regimens are marginally efficient in tumor cells being particularly resistant to radiotherapy and/or chemotherapy.
  • We hypothesized that unresponsiveness of tumors to conventional therapeutic agents might be due to inappropriate gene expression resulting from epigenetic modifications and leading to transcriptional silencing.
  • The goal of this study was to evaluate the anticancer effect of a histone deacetylase inhibitor, valproate, on mesothelioma cells in combination with pemetrexed and cisplatin, the usual first-line regimen of chemotherapy for this tumor.
  • EXPERIMENTAL DESIGN AND RESULTS: We show that valproate augments apoptosis induced by pemetrexed and cisplatin in mesothelioma cell lines and in tumor cells from patient's biopsies.
  • Finally, valproate when combined with pemetrexed and cisplatin prevents tumor growth in mouse models of epithelioid mesothelioma.
  • CONCLUSIONS: These observations support the potential additional efficacy of valproate in combination with pemetrexed and cisplatin for treatment of malignant mesothelioma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Enzyme Inhibitors / therapeutic use. Glutamates / therapeutic use. Guanine / analogs & derivatives. Mesothelioma / drug therapy. Valproic Acid / therapeutic use
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols. Apoptosis / drug effects. Apoptosis / physiology. BH3 Interacting Domain Death Agonist Protein / drug effects. BH3 Interacting Domain Death Agonist Protein / metabolism. Caspase 8 / metabolism. Cell Line, Tumor. Cell Survival / drug effects. Cell Survival / physiology. Cyclin-Dependent Kinase Inhibitor p21 / agonists. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Cytochromes c / drug effects. Cytochromes c / metabolism. Drug Synergism. Histones / drug effects. Histones / metabolism. Humans. Mice. Mice, Inbred BALB C. Mice, SCID. Mitochondria / drug effects. Mitochondria / metabolism. Pemetrexed. Reactive Oxygen Species / metabolism

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. GUANINE .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19351772.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BH3 Interacting Domain Death Agonist Protein; 0 / BID protein, human; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Enzyme Inhibitors; 0 / Glutamates; 0 / Histones; 0 / Reactive Oxygen Species; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; 614OI1Z5WI / Valproic Acid; 9007-43-6 / Cytochromes c; EC 3.4.22.- / Caspase 8; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Beseth BD, Cameron RB, Leland P, You L, Varricchio F, Kreitman RJ, Maki RA, Jablons DM, Husain SR, Puri RK: Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts. Ann Thorac Surg; 2004 Aug;78(2):436-43; discussion 436-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts.
  • BACKGROUND: Malignant pleural mesothelioma (MPM) is an uncommon but highly fatal neoplasm for which only limited treatment is available.
  • METHODS: Immunohistochemical analysis was used to determine the expression of interleukin-4 receptors (IL-4R) on mesothelioma cell lines and resected mesothelioma tumors.
  • The toxicity of this molecule to mesothelioma cell lines was tested using a protein synthesis inhibition assay.
  • A human mesothelioma xenograft model was then developed to assess the efficacy of this molecule in vivo.
  • Immunohistochemical analysis of resected mesothelioma tumor specimens from 13 patients revealed that all tumors expressed moderate-to-high levels of IL-4R.
  • Coculture of malignant mesothelioma cell lines with IL-4(38-37)-PE38KDEL resulted in a dose-dependent inhibition of tumor cell protein synthesis through an interaction with cell-surface IL-4R.
  • In a nude mouse xenograft model of human MPM, intratumoral administration of IL-4(38-37)-PE38KDEL mediated a dose-dependent decrease in tumor volume and a dose-dependent increase in survival.

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15276492.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA093708-01A3; United States / NCI NIH HHS / CA / R01 CA093708; United States / NCI NIH HHS / CA / R01 CA093708-01A3
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Bacterial Toxins; 0 / Exotoxins; 0 / Immunotoxins; 0 / Neoplasm Proteins; 0 / Receptors, Interleukin-4; 0 / Virulence Factors; 0 / interleukin 4 (38-37)-PE38KDEL; 207137-56-2 / Interleukin-4; EC 2.4.2.- / ADP Ribose Transferases; EC 2.4.2.31 / toxA protein, Pseudomonas aeruginosa
  •  go-up   go-down


5. Gabrielson EW, Pinn ML, Testa JR, Kuhajda FP: Increased fatty acid synthase is a therapeutic target in mesothelioma. Clin Cancer Res; 2001 Jan;7(1):153-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased fatty acid synthase is a therapeutic target in mesothelioma.
  • Many common human cancer tissues express high levels of fatty acid synthase (FAS), the primary enzyme for the synthesis of fatty acids, and the differential expression of FAS between normal and neoplastic tissues has led to the consideration of FAS as a target for anticancer therapy.
  • To investigate the potential of targeting FAS for the treatment of pleural mesothelioma, we first determined whether FAS is overexpressed in human mesothelioma.
  • By immunohistochemistry, we found 22 of 30 human mesothelioma tissue samples tested to express significantly increased levels of FAS compared with normal tissues, including mesothelium.
  • To further explore FAS as a therapeutic target in mesothelioma, we established a nude mouse xenograft model for human mesothelioma using the H-Meso cell line.
  • The i.p. xenografts of this cell line have high levels of FAS expression and fatty acid synthesis pathway activity and grow along mesothelial surfaces in a manner similar to the growth pattern of human mesothelioma.
  • These results suggest that FAS may be an effective target for pharmacological therapy in a high proportion of human mesotheliomas.
  • [MeSH-major] 4-Butyrolactone / analogs & derivatives. 4-Butyrolactone / therapeutic use. Antineoplastic Agents / therapeutic use. Fatty Acid Synthases / antagonists & inhibitors. Mesothelioma / drug therapy. Neoplasms, Mesothelial / drug therapy
  • [MeSH-minor] Animals. Antifungal Agents / pharmacology. Cerulenin / pharmacology. Disease Models, Animal. Humans. Immunoenzyme Techniques. Mice. Mice, Nude. Neoplasm Transplantation. Paraffin Embedding. Prognosis. Tumor Cells, Cultured / cytology. Tumor Cells, Cultured / drug effects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BUTYROLACTONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11205903.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-06927; United States / NCI NIH HHS / CA / CA-45745
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-methylene-2-octyl-5-oxofuran-3-carboxylic acid; 0 / Antifungal Agents; 0 / Antineoplastic Agents; 17397-89-6 / Cerulenin; EC 2.3.1.85 / Fatty Acid Synthases; OL659KIY4X / 4-Butyrolactone
  •  go-up   go-down


6. Littlejohn JE, Cao X, Miller SD, Ozvaran MK, Jupiter D, Zhang L, Rodarte C, Smythe WR: Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts. Int J Cancer; 2008 Jul 1;123(1):202-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts.
  • Bcl-xL functions as a dominant regulator of apoptotic cell death and is implicated in chemotherapeutic resistance of malignant pleural mesothelioma (MPM).
  • Mesothelioma cell lines demonstrate increasing levels of Bcl-xL as resistant clones are selected in vitro.
  • Here we describe the therapeutic effects of a novel combination therapy, Bcl-xL antisense oligonucleotide (ASO 15999) and cisplatin, on mesothelioma cell lines in vitro and in vivo; in addition, efficacy of ASO 15999 in decreasing tumor load as well as its effect on survival in an animal model.
  • This novel combination, with doses of cisplatin four times below established IC(50) levels, significantly decreased viability of MPM cell lines after 48 hr.
  • The growth of established mouse flank human tumor xenografts was reduced with intra-tumor administration of ASO 15999.
  • Local spread and development of IP xenografts was reduced with treatments of ASO alone, and survival of mice afflicted with these xenografts was prolonged after administration of ASO alone and ASO 15999 + cisplatin combination therapy.
  • ASO 15999 induced reduction of Bcl-xL is effective in slowing the progression of human mesothelioma cell lines both in vitro and in vivo.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Mesothelioma / drug therapy. Oligonucleotides, Antisense / pharmacology. Pleural Neoplasms / drug therapy. bcl-X Protein / pharmacology
  • [MeSH-minor] Analysis of Variance. Animals. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Cell Line, Tumor. Cisplatin / administration & dosage. Humans. Inhibitory Concentration 50. Injections, Intraperitoneal. Kaplan-Meier Estimate. Mice. Mice, SCID. Time Factors. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18360826.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1R01CA098545-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BCL2L1 protein, human; 0 / Oligonucleotides, Antisense; 0 / bcl-X Protein; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Yanagihara K, Tsumuraya M, Takigahira M, Mihara K, Kubo T, Ohuchi K, Seyama T: An orthotopic implantation mouse model of human malignant pleural mesothelioma for in vivo photon counting analysis and evaluation of the effect of S-1 therapy. Int J Cancer; 2010 Jun 15;126(12):2835-46
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An orthotopic implantation mouse model of human malignant pleural mesothelioma for in vivo photon counting analysis and evaluation of the effect of S-1 therapy.
  • Human malignant pleural mesothelioma (HMPM) is an aggressive neoplasm that is highly resistant to conventional therapies.
  • We established 3 HMPM cell lines (TCC-MESO-1, TCC-MESO-2 and TCC-MESO-3) from Japanese patients; the first 2 from the primary and metastatic tumors of a patient with the epithelioid type of HMPM, and the third from a patient with biphasic characteristics of the tumor (epithelioid and sarcomatous phenotypes).
  • Oral administration of S-1, an anticancer agent, suppressed the proliferation of the luciferase gene-expressing Me1Tu subline in the mouse models in vivo, with a treated-to-control ratio of the mean tumor volume of 0.2.
  • The orthotopic implantation mouse model proved to be useful for quantitative evaluation of the efficacy of novel anticancer drugs and also for studying the biology of HMPMs in vivo.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Disease Models, Animal. Mesothelioma / drug therapy. Oxonic Acid / administration & dosage. Photons. Pleural Neoplasms / drug therapy. Tegafur / administration & dosage
  • [MeSH-minor] Administration, Oral. Animals. Cell Line, Transformed. Cell Proliferation / drug effects. Cell Survival. Cytokines / metabolism. Drug Combinations. Humans. Immunoenzyme Techniques. Luciferases / metabolism. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Mice, SCID. Middle Aged. Neoplasm Proteins / metabolism. Tumor Cells, Cultured. Tumor Suppressor Protein p53 / genetics. Xenograft Model Antitumor Assays


8. Chua TC, Yao P, Akther J, Morris DL: Impact of tumor angiogenesis in peritoneal mesothelioma after radical cytoreduction and hyperthermic intraperitoneal chemotherapy. Pathol Oncol Res; 2010 Jun;16(2):217-22
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of tumor angiogenesis in peritoneal mesothelioma after radical cytoreduction and hyperthermic intraperitoneal chemotherapy.
  • Peritoneal mesothelioma is one of the peritoneal surface malignancies where long-term survival is a reality after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
  • Tumor angiogenesis has been shown to be of prognostic significance on survival in mesothelioma.
  • We investigated the impact of survival of patients with peritoneal mesothelioma following CRS and HIPEC to determine the impact of tumor angiogenesis on survival after this radical surgical treatment.
  • The immunostaining was performed using monoclonal mouse anti-human antibodies (VEGF-C and CD31) on an autostainer (Autostainer Plus; Dako, Inc.).
  • After CRS and HIPEC, our results demonstrate that the prognostic significance of tumor angiogenesis is negated, highlighting the potential importance of other co-contributory mechanisms in mesotheliomagenesis and undergoing radial treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hyperthermia, Induced. Mesothelioma / pathology. Neovascularization, Pathologic / pathology. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD31 / metabolism. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Humans. Image Processing, Computer-Assisted. Immunohistochemistry. Infusions, Intralesional. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1995 Feb 15;55(4):792-8 [7850791.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4833-6 [17214348.001]
  • [Cites] Acta Cytol. 1987 May-Jun;31(3):369-73 [3035848.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):603-10 [12594815.001]
  • [Cites] Virchows Arch. 1999 Jul;435(1):8-12 [10431840.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1698-704 [18375898.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):1011-27 [15585754.001]
  • [Cites] Am J Pathol. 1987 Dec;129(3):448-62 [2827488.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10397-402 [16798876.001]
  • [Cites] J Pathol. 2001 Apr;193(4):468-75 [11276005.001]
  • [Cites] J Thorac Cardiovasc Surg. 2009 Feb;137(2):453-8 [19185169.001]
  • [Cites] Lung Cancer. 2004 Aug;45 Suppl 1:S21-3 [15261428.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):29-42 [7826158.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(14):2451-60 [9059333.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6881-9 [16192580.001]
  • [Cites] Chest. 2003 Nov;124(5):1916-23 [14605068.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):2-17 [11836664.001]
  • [Cites] Ann Oncol. 2007 May;18(5):827-34 [17130182.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):573-83 [12154350.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4169-75 [12154012.001]
  • [Cites] Clin Lung Cancer. 2003 Nov;5(3):177-81 [14667274.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5334-8 [8968079.001]
  • [Cites] Thorax. 2008 Apr;63(4):345-51 [18086752.001]
  • [Cites] Br J Cancer. 1999 Sep;81(1):54-61 [10487612.001]
  • [Cites] Br J Cancer. 2001 Sep 14;85(6):863-8 [11556838.001]
  • [Cites] Chest. 2005 Nov;128(5):3382-7 [16304288.001]
  • [Cites] Can J Surg. 2009 Feb;52(1):59-64 [19234654.001]
  • (PMID = 19789996.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Vascular Endothelial Growth Factor A; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Catassi A, Paleari L, Servent D, Sessa F, Dominioni L, Ognio E, Cilli M, Vacca P, Mingari M, Gaudino G, Bertino P, Paolucci M, Calcaterra A, Cesario A, Granone P, Costa R, Ciarlo M, Alama A, Russo P: Targeting alpha7-nicotinic receptor for the treatment of pleural mesothelioma. Eur J Cancer; 2008 Oct;44(15):2296-311
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting alpha7-nicotinic receptor for the treatment of pleural mesothelioma.
  • Human malignant pleural mesothelioma (MPM) is a dreadful disease and there is still no standard therapy available for a consistent therapeutic approach.
  • This research is aimed at the evaluation of the potential therapeutic effect of a specific nicotinic receptor (nAChR) antagonist, namely alpha-Cobratoxin (alpha-CbT).
  • Its effectiveness was tested in mesothelioma cell lines and in primary mesothelioma cells in vitro, as well as in vivo, in orthotopically xenotransplanted NOD/SCID mice.
  • Non-immunogenic derivatives of the alpha-CbT molecule need to be developed for possible human use.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cobra Neurotoxin Proteins / therapeutic use. Mesothelioma / drug therapy. Nicotinic Antagonists / therapeutic use. Pleural Neoplasms / drug therapy. Receptors, Nicotinic / metabolism
  • [MeSH-minor] Animals. Apoptosis / drug effects. Dose-Response Relationship, Drug. Drug Evaluation, Preclinical / methods. Humans. Mice. Mice, Inbred NOD. Mice, SCID. Neoplasm Proteins / metabolism. Neoplasm Transplantation. Reverse Transcriptase Polymerase Chain Reaction / methods. Transplantation, Heterologous. Tumor Cells, Cultured. alpha7 Nicotinic Acetylcholine Receptor

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18722110.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chrna7 protein, human; 0 / Chrna7 protein, mouse; 0 / Cobra Neurotoxin Proteins; 0 / Neoplasm Proteins; 0 / Nicotinic Antagonists; 0 / Receptors, Nicotinic; 0 / alpha7 Nicotinic Acetylcholine Receptor; 69344-74-7 / alpha-cobratoxin
  •  go-up   go-down


10. Chua TC, Yao P, Akther J, Young L, Bao S, Samaraweera U, Yan TD, Morris DL: Differential expression of Ki-67 and sex steroid hormone receptors between genders in peritoneal mesothelioma. Pathol Oncol Res; 2009 Dec;15(4):671-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of Ki-67 and sex steroid hormone receptors between genders in peritoneal mesothelioma.
  • Gender influence on survival in mesothelioma has been observed in several large clinical series.
  • Twenty patients were treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in our peritonectomy unit.
  • The immunostaining was performed using monoclonal mouse anti-human antibodies on an autostainer (Autostainer Plus; Dako, Inc.).
  • For the first time, we demonstrate the presence of sex steroid receptors in peritoneal mesothelioma.
  • Once the exact functional effects of these receptors are understood, the use of established therapeutic options that are clinically available to target the sex steroid pathway may become a reality.
  • [MeSH-major] Ki-67 Antigen / metabolism. Mesothelioma / metabolism. Peritoneal Neoplasms / metabolism. Receptors, Androgen / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Sex Characteristics

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2006 Dec;93(12):1536-42 [17048277.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7721-35 [16234531.001]
  • [Cites] Ann Oncol. 2007 Jun;18(6):985-90 [17030547.001]
  • [Cites] J Invest Dermatol. 1989 Jul;93(1):178-82 [2746003.001]
  • [Cites] Endocr Rev. 1999 Jun;20(3):321-44 [10368774.001]
  • [Cites] Eur J Surg Oncol. 2006 Aug;32(6):676-81 [16616827.001]
  • [Cites] J Thorac Cardiovasc Surg. 2008 Mar;135(3):620-6, 626.e1-3 [18329481.001]
  • [Cites] Anticancer Res. 2001 Nov-Dec;21(6A):3871-4 [11911261.001]
  • [Cites] J Thorac Cardiovasc Surg. 2006 May;131(5):981-7 [16678579.001]
  • [Cites] Int Arch Occup Environ Health. 2004 Apr;77(3):191-9 [14991330.001]
  • [Cites] Ann Thorac Surg. 2008 May;85(5):1740-6 [18442576.001]
  • [Cites] Mol Cancer. 2002 Nov 14;1:7 [12473178.001]
  • [Cites] Tumori. 2003 May-Jun;89(3):269-73 [12908781.001]
  • [Cites] Steroids. 2000 Oct-Nov;65(10-11):545-9 [11108858.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):370-3 [18156144.001]
  • [Cites] Ann Thorac Surg. 1999 Nov;68(5):1799-804 [10585061.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):29-42 [7826158.001]
  • [Cites] Ann Oncol. 2007 May;18(5):827-34 [17130182.001]
  • [Cites] Respir Med. 2001 Oct;95(10):829-35 [11601750.001]
  • [Cites] J Cell Physiol. 2000 Mar;182(3):311-22 [10653597.001]
  • [Cites] Endocr Rev. 1990 May;11(2):201-20 [2194782.001]
  • [Cites] Endocr Rev. 2007 Dec;28(7):778-808 [17940184.001]
  • [Cites] Clin Lung Cancer. 2005 Jul;7(1):40-6 [16098243.001]
  • [Cites] Am J Med. 1980 Mar;68(3):356-62 [7361805.001]
  • [Cites] Oncologist. 2008 Jan;13(1):16-24 [18245009.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1591-603 [16221782.001]
  • [Cites] N Engl J Med. 1989 Feb 23;320(8):479-84 [2644532.001]
  • [Cites] Am J Clin Pathol. 2006 Jan;125(1):67-76 [16482993.001]
  • [Cites] Chest. 1996 Jan;109(1):109-14 [8549169.001]
  • [Cites] Cancer. 1986 Oct 1;58(7):1540-51 [3742473.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jul;12(3):605-21, xi [14567020.001]
  • [Cites] Hum Reprod Update. 2005 May-Jun;11(3):309-17 [15790600.001]
  • [Cites] Hum Pathol. 2003 Apr;34(4):369-74 [12733118.001]
  • [Cites] Endocr Rev. 2004 Feb;25(1):45-71 [14769827.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):145-52 [9440736.001]
  • [Cites] Eur J Surg Oncol. 2006 Nov;32(9):948-53 [16806796.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • (PMID = 19401830.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Androgen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


11. Tabata C, Tabata R, Hirayama N, Yasumitsu A, Yamada S, Murakami A, Iida S, Tamura K, Terada T, Kuribayashi K, Fukuoka K, Nakano T: All-trans-retinoic acid inhibits tumour growth of malignant pleural mesothelioma in mice. Eur Respir J; 2009 Nov;34(5):1159-67
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] All-trans-retinoic acid inhibits tumour growth of malignant pleural mesothelioma in mice.
  • Malignant pleural mesothelioma (MPM) is an aggressive malignant tumour of mesothelial origin associated with asbestos exposure.
  • Because MPM has limited response to conventional chemotherapy and radiotherapy, the prognosis is very poor.
  • We investigated whether ATRA had an inhibitory effect on the cell growth of MPM, the origin of which was mesenchymal cells similar to lung fibroblasts, using a subcutaneous xenograft mouse model.
  • These data may provide a rationale to explore the clinical use of ATRA for the treatment of MPM.
  • [MeSH-major] Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy. Tretinoin / pharmacology

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. ASBESTOS .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19443527.001).
  • [ISSN] 1399-3003
  • [Journal-full-title] The European respiratory journal
  • [ISO-abbreviation] Eur. Respir. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / Platelet-Derived Growth Factor; 0 / Proto-Oncogene Proteins c-sis; 0 / RNA, Messenger; 0 / Transforming Growth Factor beta1; 0 / platelet-derived growth factor BB; 1332-21-4 / Asbestos; 5688UTC01R / Tretinoin; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  •  go-up   go-down


12. Paik PK, Krug LM: Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials. J Thorac Oncol; 2010 Feb;5(2):275-9
Hazardous Substances Data Bank. Vorinostat .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials.
  • Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer of the mesothelium with only a limited range of treatment options that are largely ineffective in improving survival.
  • Recent efforts have turned toward the analysis of specific, dysregulated biologic pathways for insight into new treatment targets.
  • An increasing amount of preclinical data highlighting the effectiveness of histone deacetylase inhibition in MPM cell lines and mouse xenograft models has led to a number of early phase clinical trials in patients with MPM.
  • The results of these efforts have led to a multicenter, randomized, placebo-controlled phase III study of the histone deacetylase inhibitor vorinostat in patients with advanced MPM, offering hope for a new and effective therapy in patients with this disease.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Histone Deacetylase Inhibitors / pharmacology. Histone Deacetylase Inhibitors / therapeutic use. Hydroxamic Acids / pharmacology. Hydroxamic Acids / therapeutic use. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy
  • [MeSH-minor] Animals. Clinical Trials as Topic. Drug Evaluation. Drug Evaluation, Preclinical. Humans. Mice

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2005 Feb 10;24(7):1302-8 [15592515.001]
  • [Cites] Am J Respir Cell Mol Biol. 2001 Nov;25(5):562-8 [11713097.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2586-96 [12239173.001]
  • [Cites] Nat Genet. 2002 Dec;32(4):606-13 [12402037.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 30;314(1):186-91 [14715264.001]
  • [Cites] Am J Epidemiol. 2004 Jan 15;159(2):107-12 [14718210.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1813-25 [15014036.001]
  • [Cites] Prostate. 2004 May 1;59(2):177-89 [15042618.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6962-8 [15501975.001]
  • [Cites] J Thorac Cardiovasc Surg. 1991 Jul;102(1):1-9 [2072706.001]
  • [Cites] Mech Dev. 1993 Jan;40(1-2):85-97 [8382938.001]
  • [Cites] Oncogene. 1994 Jun;9(6):1781-90 [8183577.001]
  • [Cites] J Pathol. 1997 Jan;181(1):67-74 [9072005.001]
  • [Cites] J Thorac Cardiovasc Surg. 1998 Feb;115(2):310-7; discussion 317-8 [9475525.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jan;117(1):54-63; discussion 63-5 [9869758.001]
  • [Cites] Chest Surg Clin N Am. 1999 May;9(2):327-38, x [10365266.001]
  • [Cites] Nat Genet. 2005 Apr;37(4):391-400 [15765097.001]
  • [Cites] APMIS. 2005 Apr;113(4):264-8 [15865607.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3923-31 [15897550.001]
  • [Cites] Lancet. 2005 Jul 30-Aug 5;366(9483):397-408 [16054941.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6881-9 [16192580.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Dec;19(6):1117-36, vii [16325127.001]
  • [Cites] J Biol Chem. 2006 May 12;281(19):13548-58 [16533812.001]
  • [Cites] Nat Rev Drug Discov. 2006 Sep;5(9):769-84 [16955068.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Apr;7(4):583-98 [17428177.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3605-10 [17510206.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1196-202 [17429100.001]
  • [Cites] Acta Biochim Biophys Sin (Shanghai). 2007 Dec;39(12):931-8 [18064385.001]
  • [Cites] J Clin Oncol. 2007 Dec 20;25(36):5777-84 [18089875.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3543-51 [18506025.001]
  • [Cites] J Thorac Oncol. 2009 Jan;4(1):97-101 [19096314.001]
  • [Cites] J Thorac Oncol. 2009 Feb;4(2):149-60 [19179889.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1227-34 [19188680.001]
  • [Cites] Expert Opin Investig Drugs. 2009 Apr;18(4):501-8 [19335278.001]
  • [Cites] Clin Cancer Res. 2009 Apr 15;15(8):2818-28 [19351772.001]
  • [Cites] Cancer Causes Control. 2009 Aug;20(6):935-44 [19294523.001]
  • [Cites] Mol Cancer Ther. 2009 Jun;8(6):1409-20 [19509247.001]
  • [Cites] J Clin Oncol. 2009 Jun 20;27(18):3007-13 [19364962.001]
  • [Cites] Br J Ind Med. 1960 Oct;17:260-71 [13782506.001]
  • [Cites] Science. 2001 Aug 10;293(5532):1074-80 [11498575.001]
  • [Cites] Jpn J Cancer Res. 2001 Dec;92(12):1300-4 [11749695.001]
  • (PMID = 20035240.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009207
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 58IFB293JI / vorinostat
  • [Number-of-references] 47
  • [Other-IDs] NLM/ NIHMS589324; NLM/ PMC4052955
  •  go-up   go-down


13. Merrell MA, Wakchoure S, Ilvesaro JM, Zinn K, Gehrs B, Lehenkari PP, Harris KW, Selander KS: Differential effects of Ca(2+) on bisphosphonate-induced growth inhibition in breast cancer and mesothelioma cells. Eur J Pharmacol; 2007 Mar 15;559(1):21-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential effects of Ca(2+) on bisphosphonate-induced growth inhibition in breast cancer and mesothelioma cells.
  • Pre-clinical studies indicate that bisphosphonates also inhibit the growth of various cancer cells in vitro, but their in vivo anti-cancer activity varies greatly, depending on the tumor type.
  • We compared the various cellular effects of bisphosphonates in breast cancer and mesothelioma cells, with differences in growth inhibition responses to bisphosphonate-treatment in vivo.
  • Furthermore, excess pyrophosphate-resembling bisphosphonates prevent nitrogen-containing-bisphosphonate-induced accumulation of unprenylated Rap1A, p38 phosphorylation and growth inhibition in human MDA-MB-231 breast cancer and mouse AB-12 mesothelioma cells.
  • In conclusion, our results suggest that Ca(2+) regulates the growth inhibitory effects of bisphosphonates in a target cell and drug-specific fashion.
  • These findings may be of physiological relevance since many tumor types are calcified.
  • They further suggest that bisphosphonates can accumulate in tumors that are growing at the visceral sites and that differences in tumor accumulation of bisphosphonates may regulate their in vivo sensitivity to these drugs.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Calcium / pharmacology. Diphosphonates / pharmacology. Mesothelioma / drug therapy. Mesothelioma / pathology
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Cell Survival / drug effects. Connexin 43 / biosynthesis. Female. Flow Cytometry. Fluorescent Dyes. Humans. Isoquinolines. Nitrogen / chemistry. Radiopharmaceuticals. Receptors, Antigen, T-Cell / drug effects. Technetium Tc 99m Medronate. p38 Mitogen-Activated Protein Kinases / biosynthesis. p38 Mitogen-Activated Protein Kinases / genetics. rap1 GTP-Binding Proteins / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. Nitrogen, Elemental .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214981.001).
  • [ISSN] 0014-2999
  • [Journal-full-title] European journal of pharmacology
  • [ISO-abbreviation] Eur. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Connexin 43; 0 / Diphosphonates; 0 / Fluorescent Dyes; 0 / Isoquinolines; 0 / Radiopharmaceuticals; 0 / Receptors, Antigen, T-Cell; 9654F8OVKE / lucifer yellow; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 3.6.5.2 / rap1 GTP-Binding Proteins; N762921K75 / Nitrogen; SY7Q814VUP / Calcium; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


14. Tomasetti M, Gellert N, Procopio A, Neuzil J: A vitamin E analogue suppresses malignant mesothelioma in a preclinical model: a future drug against a fatal neoplastic disease? Int J Cancer; 2004 May 1;109(5):641-2
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A vitamin E analogue suppresses malignant mesothelioma in a preclinical model: a future drug against a fatal neoplastic disease?
  • Malignant mesothelioma is a fatal type of neoplasia of the pleura and the peritoneum with currently no known cure.
  • Therefore, discovery of an efficient antimesothelioma drug with low deleterious side effects is desirable.
  • Here, we studied in vivo the effect of alpha-tocopheryl succinate, a semisynthetic vitamin E analogue with proapoptotic and anticancer activity and selectivity for malignant cells, on experimental peritoneal mesothelioma using immunocompromised mice.
  • Our finding warrants further testing of vitamin E analogues as potential antimesothelioma drugs.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Membrane Glycoproteins / drug effects. Mesothelioma / drug therapy. Peritoneal Neoplasms / drug therapy. Tumor Necrosis Factor-alpha / drug effects. Vitamin E / analogs & derivatives. Vitamin E / pharmacology
  • [MeSH-minor] Animals. Apoptosis Regulatory Proteins. Cell Line, Tumor. Humans. Immunocompromised Host. Mice. Mice, Nude. TNF-Related Apoptosis-Inducing Ligand. Time Factors. Tocopherols. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Vitamin E.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 14999768.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Apoptosis Regulatory Proteins; 0 / Membrane Glycoproteins; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / Tnfsf10 protein, mouse; 0 / Tumor Necrosis Factor-alpha; 1406-18-4 / Vitamin E; 1406-66-2 / Tocopherols
  •  go-up   go-down


15. Triozzi PL, Aldrich W, Allen KO, Lima J, Shaw DR, Strong TV: Antitumor activity of the intratumoral injection of fowlpox vectors expressing a triad of costimulatory molecules and granulocyte/macrophage colony stimulating factor in mesothelioma. Int J Cancer; 2005 Jan 20;113(3):406-14
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antitumor activity of the intratumoral injection of fowlpox vectors expressing a triad of costimulatory molecules and granulocyte/macrophage colony stimulating factor in mesothelioma.
  • The activity of the intratumoral administration of recombinant fowlpox vectors expressing a triad of costimulatory molecules (rF-TRICOM) was evaluated in the asbestos-induced AB12 and AC29 mouse models of mesothelioma.
  • Mesothelioma cell infected with rF-TRICOM expressed high levels of the costimulatory molecules.
  • Tumor regressions were associated with the development of serum IgG reactivities to mesothelioma-associated determinants and specific systemic cytolytic activity, and responding mice were capable of rejecting tumors upon re-challenge.
  • Production of GM-CSF decreased in vivo in tumors injected with rF-TRICOM. rF-TRICOM and wild-type fowlpox inhibited the growth of AB12 and AC29 cells in vitro; less inhibition was observed with rF-GM-CSF.
  • These results indicate that the intratumoral injection of rF-TRICOM has significant activity in mouse models of mesothelioma and can elicit a systemic antitumor immune response.
  • The results also suggest potential limitations to the intratumoral administration of cytokines, such as GM-CSF, in mesothelioma.
  • [MeSH-major] Fowlpox / genetics. Genetic Vectors / therapeutic use. Granulocyte-Macrophage Colony-Stimulating Factor / immunology. Mesothelioma / therapy. Vaccines, Synthetic / therapeutic use
  • [MeSH-minor] Animals. Asbestos / toxicity. Birds. Cancer Vaccines. Carcinogens / toxicity. Cell Proliferation / drug effects. DNA, Recombinant. Female. Immunoglobulin G / blood. Mice. Mice, Inbred BALB C. Mice, Inbred CBA. Survival Rate. Vaccination

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15455351.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5P30CA13148
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Carcinogens; 0 / DNA, Recombinant; 0 / Immunoglobulin G; 0 / Vaccines, Synthetic; 0 / rF-TRICOM vaccine; 1332-21-4 / Asbestos; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


16. Suzuki E, Kapoor V, Cheung HK, Ling LE, DeLong PA, Kaiser LR, Albelda SM: Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity. Clin Cancer Res; 2004 Sep 1;10(17):5907-18
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
  • PURPOSE: Transforming growth factor (TGF)-beta blockade has been proposed as an anticancer therapy; however, understanding which tumor patients might benefit most from such therapy is crucial.
  • An ideal target of such inhibitory therapy might be malignant mesothelioma (MM), a highly lethal, treatment-resistant malignancy of mesothelial cells of the pleura and peritoneum that produces large amounts of TGF-beta.
  • The purpose of this study was to explore the possible therapeutic utility of TGF-beta blockade on MM.
  • EXPERIMENTAL DESIGN: To evaluate this hypothesis, we tested the effects of a soluble TGF-beta type II receptor (sTGF-beta R) that specifically inhibits TGF-beta1 and TGF-beta 3 in three different murine MM tumor models, AB12 and AC29 (which produce large amounts of TGF-beta) and AB1 (which does not produce TGF-beta).
  • [MeSH-major] Mesothelioma / therapy. Receptors, Transforming Growth Factor beta / therapeutic use. Transforming Growth Factor beta / antagonists & inhibitors
  • [MeSH-minor] Animals. Antigens, CD95 / metabolism. CD4-Positive T-Lymphocytes / immunology. CD4-Positive T-Lymphocytes / metabolism. CD4-Positive T-Lymphocytes / pathology. CD8-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / metabolism. CD8-Positive T-Lymphocytes / pathology. Female. Genes, MHC Class I / physiology. Genes, MHC Class II / physiology. Lymphocyte Depletion. Mice. Mice, Inbred BALB C. Mice, Inbred CBA. Mice, SCID. Protein-Serine-Threonine Kinases. Spleen / immunology. Spleen / metabolism. Spleen / pathology. T-Lymphocytes, Cytotoxic / drug effects. T-Lymphocytes, Cytotoxic / immunology. T-Lymphocytes, Cytotoxic / metabolism. Transforming Growth Factor beta1. Transforming Growth Factor beta3. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15355924.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / PHS HHS / / P01 66726
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Receptors, Transforming Growth Factor beta; 0 / Tgfb1 protein, mouse; 0 / Tgfb3 protein, mouse; 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1; 0 / Transforming Growth Factor beta3; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  •  go-up   go-down


17. Ikuta K, Yano S, Trung VT, Hanibuchi M, Goto H, Li Q, Wang W, Yamada T, Ogino H, Kakiuchi S, Uehara H, Sekido Y, Uenaka T, Nishioka Y, Sone S: E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles. Clin Cancer Res; 2009 Dec 1;15(23):7229-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles.
  • PURPOSE: Malignant pleural mesothelioma (MPM) is a biologically heterogeneous malignant disease with a poor prognosis.
  • We reported previously that the anti-vascular endothelial growth factor (VEGF) antibody, bevacizumab, effectively inhibited the progression of VEGF-high-producing (but not VEGF-low-producing) MPM cells in orthotopic implantation models, indicating the need for novel therapeutic strategies to improve the poor prognosis of this disease.
  • Therefore, we focused on the multi-tyrosine kinase inhibitor E7080 and assessed its therapeutic efficacy against MPM cells with different proangiogenic cytokine production profiles.
  • EXPERIMENTAL DESIGN: The efficacy of E7080 was assayed in orthotopic implantation of severe combined immunodeficient mouse models with three human MPM cell lines (MSTO-211H, NCI-H290, and Y-MESO-14).
  • Orthotopically inoculated MSTO-211H cells produced only thoracic tumors, whereas NCI-H290 and Y-MESO-14 cells also developed pleural effusions.
  • Treatment with E7080 potently inhibited the progression of these three MPM cell lines and markedly prolonged mouse survival, which was associated with decreased numbers of tumor-associated vessels and proliferating MPM cells in the tumor.
  • [MeSH-major] Cytokines / biosynthesis. Mesothelioma / drug therapy. Mesothelioma / pathology. Neovascularization, Pathologic. Phenylurea Compounds / pharmacology. Pleural Neoplasms / drug therapy. Pleural Neoplasms / pathology. Quinolines / pharmacology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19934291.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Phenylurea Compounds; 0 / Platelet-Derived Growth Factor; 0 / Quinolines; 0 / Vascular Endothelial Growth Factor A; 0 / platelet-derived growth factor A; 103107-01-3 / Fibroblast Growth Factor 2; EE083865G2 / lenvatinib
  •  go-up   go-down


19. van der Most RG, Currie AJ, Mahendran S, Prosser A, Darabi A, Robinson BW, Nowak AK, Lake RA: Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. Cancer Immunol Immunother; 2009 Aug;58(8):1219-28
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy.
  • However, the efficacy of anti-tumor chemotherapy may be limited by tumor-driven immunosuppression, e.g., through CD25+ regulatory T cells.
  • We addressed this question in a mouse model of mesothelioma by depleting or reconstituting CD25+ regulatory T cells in combination with two different chemotherapeutic drugs.
  • Analysis of post-chemotherapy regulatory T cell populations revealed that cyclophosphamide depleted cycling (Ki-67(hi)) T cells, including foxp3+ regulatory CD4+ T cells.
  • Our data suggest that regulatory T cell depletion could be used to improve the efficacy of anti-cancer chemotherapy regimens.
  • Indeed, we observed that the drug gemcitabine, which does not deplete cycling regulatory T cells, eradicates established tumors in mice only when CD25+ CD4+ T cells are concurrently depleted.
  • Cyclophosphamide could be used to achieve regulatory T cell depletion in combination with chemotherapy.
  • [MeSH-major] CD8-Positive T-Lymphocytes / immunology. Cyclophosphamide / therapeutic use. Immunosuppressive Agents / therapeutic use. Lymphocyte Depletion. Mesothelioma / drug therapy. Receptors, Tumor Necrosis Factor, Type II / immunology. T-Lymphocytes, Regulatory / drug effects
  • [MeSH-minor] Adoptive Transfer. Animals. Antigens, Differentiation, T-Lymphocyte / immunology. Antigens, Differentiation, T-Lymphocyte / metabolism. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Inducible T-Cell Co-Stimulator Protein. Kaplan-Meier Estimate. Ki-67 Antigen / immunology. Ki-67 Antigen / metabolism. L-Selectin / immunology. L-Selectin / metabolism. Mice. Mice, Inbred BALB C. Mice, Nude

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19052741.001).
  • [ISSN] 1432-0851
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Icos protein, mouse; 0 / Immunosuppressive Agents; 0 / Inducible T-Cell Co-Stimulator Protein; 0 / Ki-67 Antigen; 0 / Mki67 protein, mouse; 0 / Receptors, Tumor Necrosis Factor, Type II; 0W860991D6 / Deoxycytidine; 126880-86-2 / L-Selectin; 8N3DW7272P / Cyclophosphamide; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


20. Altomare DA, You H, Xiao GH, Ramos-Nino ME, Skele KL, De Rienzo A, Jhanwar SC, Mossman BT, Kane AB, Testa JR: Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene; 2005 Sep 8;24(40):6080-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth.
  • The phosphatidylinositol 3-kinase (PI3K)/AKT pathway has been implicated in tumor aggressiveness, in part by mediating cell survival and reducing sensitivity to chemotherapy.
  • Treatment of this cell line with the mTOR inhibitor rapamycin resulted in growth arrest in G1 phase.
  • Treatment of MM cells with the PI3K inhibitor LY294002 in combination with cisplatin had greater efficacy in inhibiting cell proliferation and inducing apoptosis than either agent alone.
  • These findings also suggest that mouse models of MM may be useful for future preclinical studies of pharmaceuticals targeting the PI3K/AKT pathway.

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15897870.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA077429; United States / NIEHS NIH HHS / ES / ES-003721; United States / NCI NIH HHS / CA / R01 CA045745; United States / NCI NIH HHS / CA / CA-77429; United States / NCI NIH HHS / CA / CA-45745; United States / NCI NIH HHS / CA / P30 CA006927; United States / NCI NIH HHS / CA / CA-06927
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Proteins; EC 2.7.- / Protein Kinases; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.- / Phosphoric Monoester Hydrolases; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


21. Inami K, Abe M, Takeda K, Hagiwara Y, Maeda M, Segawa T, Suyama M, Watanabe S, Hino O: Antitumor activity of anti-C-ERC/mesothelin monoclonal antibody in vivo. Cancer Sci; 2010 Apr;101(4):969-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mesothelioma is an aggressive cancer often caused by chronic asbestos exposure, and its prognosis is very poor despite the therapies currently used.
  • Thus, novel effective therapies are warranted to improve the prognosis.
  • In this study, we investigated the antitumor activity of C-ERC/mesothelin-specific mouse monoclonal antibody, 22A31, against tumors derived from a human mesothelioma cell line, ACC-MESO-4, in a xenograft experimental model using female BALB/c athymic nude mice.
  • Treatment with 22A31 did not inhibit cell proliferation of ACC-MESO-4 in vitro; however, therapeutic treatment with 22A31 drastically inhibited tumor growth in vivo.
  • 22A31 could have potential as a therapeutic tool to treat C-ERC/mesothelin-expressing cancers including mesothelioma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Membrane Glycoproteins / immunology. Mesothelioma / therapy
  • [MeSH-minor] Animals. Antibody-Dependent Cell Cytotoxicity / drug effects. Antibody-Dependent Cell Cytotoxicity / immunology. Female. GPI-Linked Proteins. Humans. Killer Cells, Natural / immunology. Killer Cells, Natural / metabolism. Mice. Mice, Inbred BALB C. Mice, Nude. Oncogene Proteins / immunology

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20100205.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Erc protein, human; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / Oncogene Proteins; 0 / mesothelin
  •  go-up   go-down


22. van der Most RG, Currie AJ, Cleaver AL, Salmons J, Nowak AK, Mahendran S, Larma I, Prosser A, Robinson BW, Smyth MJ, Scalzo AA, Degli-Esposti MA, Lake RA: Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. PLoS One; 2009;4(9):e6982
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth.
  • BACKGROUND: Anti-cancer chemotherapy can be simultaneously lymphodepleting and immunostimulatory.
  • Pre-clinical models clearly demonstrate that chemotherapy can synergize with immunotherapy, raising the question how the immune system can be mobilized to generate anti-tumor immune responses in the context of chemotherapy.
  • METHODS AND FINDINGS: We used a mouse model of malignant mesothelioma, AB1-HA, to investigate T cell-dependent tumor resolution after chemotherapy.
  • This treatment was associated with an IFN-alpha/beta response and a profound negative impact on the anti-tumor and total CD8 T cell responses.
  • CONCLUSION: The data support a model in which chemotherapy sensitizes tumor cells for T cell-, and possibly NK cell-, mediated apoptosis.
  • [MeSH-major] Antineoplastic Agents / pharmacology. CD8-Positive T-Lymphocytes / immunology. Cyclophosphamide / pharmacology. Neoplasms / therapy. TNF-Related Apoptosis-Inducing Ligand / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 2004 Feb 16;199(4):437-48 [14769851.001]
  • [Cites] J Immunol. 2003 May 15;170(10):4905-13 [12734333.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4490-6 [12907622.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):5143-50 [12941846.001]
  • [Cites] Nat Immunol. 2003 Oct;4(10):1009-15 [14502286.001]
  • [Cites] Eur J Immunol. 2004 Feb;34(2):336-44 [14768038.001]
  • [Cites] J Immunol. 1984 Oct;133(4):1710-5 [6206131.001]
  • [Cites] Eur J Immunol. 1986 Jul;16(7):735-40 [3487457.001]
  • [Cites] Cancer Res. 1989 Apr 1;49(7):1649-54 [2522344.001]
  • [Cites] Immunology. 1990 Sep;71(1):90-5 [2145216.001]
  • [Cites] Int J Cancer. 1991 Jan 21;47(2):285-90 [1703129.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2399-409 [9746780.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1071-9 [10070965.001]
  • [Cites] J Immunol. 1999 May 15;162(10):5838-45 [10229818.001]
  • [Cites] J Immunol. 1999 Jun 1;162(11):6658-62 [10352283.001]
  • [Cites] J Immunol. 2004 Nov 15;173(10):5923-8 [15528325.001]
  • [Cites] Cancer Immunol Immunother. 2005 May;54(5):499-505 [15614529.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2862-8 [15591121.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):397-405 [15864281.001]
  • [Cites] J Exp Med. 2005 May 16;201(10):1591-602 [15883172.001]
  • [Cites] J Exp Med. 2005 Sep 5;202(5):637-50 [16129706.001]
  • [Cites] Int J Mol Med. 2005 Dec;16(6):1125-38 [16273296.001]
  • [Cites] Cancer Immunol Immunother. 2006 Jan;55(1):76-84 [15864587.001]
  • [Cites] J Exp Med. 2005 Dec 19;202(12):1691-701 [16365148.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):601-4 [16423984.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1342-51 [16223768.001]
  • [Cites] J Immunol. 2006 Mar 1;176(5):2722-9 [16493027.001]
  • [Cites] Nat Med. 2006 Jun;12(6):693-8 [16680149.001]
  • [Cites] Immunity. 2006 Jun;24(6):787-99 [16782034.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(2):280-6 [17097329.001]
  • [Cites] Cancer Biol Ther. 2007 Jun;6(6):880-5 [17582217.001]
  • [Cites] Mol Cancer. 2007;6:66 [17953743.001]
  • [Cites] Cell Death Differ. 2008 Jan;15(1):13-20 [18007666.001]
  • [Cites] Cancer Immunol Immunother. 2006 Apr;55(4):459-68 [15965646.001]
  • [Cites] Curr Protoc Cell Biol. 2004 Feb;Chapter 18:Unit 18.8 [18228448.001]
  • [Cites] Immunity. 2008 May;28(5):710-22 [18468462.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10895-900 [18667695.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11317-22 [18685088.001]
  • [Cites] Curr Opin Immunol. 2008 Oct;20(5):545-57 [18573339.001]
  • [Cites] Curr Opin Immunol. 2008 Oct;20(5):504-11 [18573340.001]
  • [Cites] Nat Rev Cancer. 2008 Oct;8(10):782-98 [18813321.001]
  • [Cites] Nature. 2008 Dec 4;456(7222):593-8 [19052619.001]
  • [Cites] J Pharmacol Exp Ther. 2009 Jan;328(1):107-15 [18829727.001]
  • [Cites] J Immunol. 2009 May 1;182(9):5217-24 [19380767.001]
  • [Cites] J Exp Med. 2004 Aug 2;200(3):297-306 [15289501.001]
  • [Cites] Eur J Biochem. 2004 Nov;271(21):4222-8 [15511228.001]
  • [Cites] Proc Natl Acad Sci U S A. 1977 May;74(5):2135-9 [266735.001]
  • [Cites] Cancer Immunol Immunother. 2009 Aug;58(8):1219-28 [19052741.001]
  • [Cites] J Immunol. 2008 Feb 1;180(3):1535-44 [18209049.001]
  • [Cites] Blood. 2000 Jan 1;95(1):212-20 [10607705.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2024-30 [10706870.001]
  • [Cites] J Exp Med. 2000 Apr 3;191(7):1241-6 [10748241.001]
  • [Cites] J Exp Med. 2001 Mar 19;193(6):661-70 [11257133.001]
  • [Cites] J Immunol. 2001 Jun 1;166(11):6608-15 [11359814.001]
  • [Cites] Am J Respir Cell Mol Biol. 2001 Jul;25(1):111-8 [11472983.001]
  • [Cites] J Immunol. 2001 Nov 1;167(9):4895-901 [11673494.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1549-59 [11733570.001]
  • [Cites] J Immunol. 2002 Feb 1;168(3):1356-61 [11801676.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2353-8 [11956096.001]
  • [Cites] Oncogene. 2003 Mar 20;22(11):1653-62 [12642868.001]
  • [Cites] Adv Immunol. 2004;84:131-79 [15246252.001]
  • (PMID = 19746156.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 82115-62-6 / Interferon-gamma; 8N3DW7272P / Cyclophosphamide
  • [Other-IDs] NLM/ PMC2734989
  •  go-up   go-down


23. Needham DJ, Lee JX, Beilharz MW: Intra-tumoural regulatory T cells: a potential new target in cancer immunotherapy. Biochem Biophys Res Commun; 2006 May 12;343(3):684-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The AE17 murine mesothelioma model was used for this study.
  • Localised, intra-tumoural depletion of T(reg) cells is a new, clinically relevant treatment option for established tumours.
  • [MeSH-major] Lymphocyte Depletion. Lymphocytes, Tumor-Infiltrating / drug effects. Neoplasms, Experimental / drug therapy. Receptors, Interleukin-2 / antagonists & inhibitors. T-Lymphocytes, Regulatory / drug effects
  • [MeSH-minor] Animals. Antibodies, Monoclonal / therapeutic use. Cell Proliferation. Female. Forkhead Transcription Factors / metabolism. Mesothelioma / drug therapy. Mesothelioma / immunology. Mesothelioma / pathology. Mice. Mice, Inbred C57BL. T-Lymphocyte Subsets / drug effects. T-Lymphocyte Subsets / immunology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16563349.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Forkhead Transcription Factors; 0 / Foxp3 protein, mouse; 0 / Receptors, Interleukin-2
  •  go-up   go-down


24. Broomfield SA, van der Most RG, Prosser AC, Mahendran S, Tovey MG, Smyth MJ, Robinson BW, Currie AJ: Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. J Immunol; 2009 May 1;182(9):5217-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Topical application of tumors with the TLR7 agonist imiquimod is an effective adjunct treatment for a range of primary dermatological cancers.
  • However, for therapy to be effective against a broad range of solid tumor types, it must promote a strong systemic antitumor response that targets metastases in addition to primary tumor.
  • We therefore investigated the potential of locally delivered imiquimod to stimulate an effective systemic antitumor response in a murine model of malignant mesothelioma (AB1-HA) with primary and distal tumors (dual tumor).
  • This local antitumor immune response required both CD8 T cells and NK cells, but not CD4 T cells, and was reliant on type I IFN induction.
  • In vivo CTL studies and Ly6A/E staining of lymphocytes suggested that local imiquimod treatment had indeed induced a systemic, Ag-specific CD8 response.
  • However, notably this response was not sufficient to retard the growth of an untreated distal tumor.
  • Because local imiquimod treatment did not induce significant CD4 T cell responses, we investigated the efficacy of combining imiquimod with agonistic CD40 Ab (as a surrogate for CD4 T cell help).
  • Combination of locally delivered imiquimod with systemic anti-CD40 immunotherapy not only significantly enhanced the local antitumor response, with 30% complete resolution, but it was also effective at significantly retarding growth of distal tumor.
  • These results demonstrate that antitumor responses induced by locally delivered TLR7 agonists can be harnessed systemically for treating distal tumor.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antigens, CD40 / immunology. Membrane Glycoproteins / agonists. Mesothelioma / immunology. Mesothelioma / therapy. Toll-Like Receptor 7 / agonists
  • [MeSH-minor] Adjuvants, Immunologic / administration & dosage. Adjuvants, Immunologic / therapeutic use. Animals. CD8-Positive T-Lymphocytes / immunology. Cell Line, Tumor. Cytotoxicity, Immunologic. Drug Therapy, Combination. Female. Interferon Type I / administration & dosage. Interferon-gamma / administration & dosage. Killer Cells, Natural / immunology. Ligands. Mice. Mice, Inbred BALB C. Mice, Knockout. Mice, Nude. Mice, Transgenic

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19380767.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antibodies, Monoclonal; 0 / Antigens, CD40; 0 / Interferon Type I; 0 / Ligands; 0 / Membrane Glycoproteins; 0 / Tlr7 protein, mouse; 0 / Toll-Like Receptor 7; 82115-62-6 / Interferon-gamma; 99011-02-6 / imiquimod
  •  go-up   go-down


25. Kim S, Buchlis G, Fridlender ZG, Sun J, Kapoor V, Cheng G, Haas A, Cheung HK, Zhang X, Corbley M, Kaiser LR, Ling L, Albelda SM: Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. Cancer Res; 2008 Dec 15;68(24):10247-56
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy.
  • This article explores the potential for increased efficacy when combining immunotherapies with TGF-beta suppression using the TGF-beta type I receptor kinase inhibitor SM16.
  • AB12 (mesothelioma) and LKR (lung cancer) tumors or intratracheally in a Kras orthotopic lung tumor model.
  • Tumor growth was assessed and cytokine expression and cell populations were measured in tumors and spleens by real-time PCR and flow cytometry.
  • Blockade of the TGF-beta signaling pathway augments the antitumor effects of Ad.IFN-beta immune-activating or Ad.E7 vaccination therapy.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Cancer Biol. 2006 Feb;16(1):3-15 [16153857.001]
  • [Cites] Semin Cancer Biol. 2006 Feb;16(1):66-72 [16298138.001]
  • [Cites] Annu Rev Immunol. 2006;24:99-146 [16551245.001]
  • [Cites] J Leukoc Biol. 2006 Apr;79(4):652-62 [16415165.001]
  • [Cites] J Immunother. 2006 May-Jun;29(3):233-40 [16699366.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5527-36 [16740684.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4721-30 [16966690.001]
  • [Cites] J Exp Med. 2006 Nov 27;203(12):2691-702 [17101732.001]
  • [Cites] J Neurooncol. 2007 Jan;81(2):149-62 [16941073.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2351-9 [17332368.001]
  • [Cites] Annu Rev Immunol. 2007;25:267-96 [17134371.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4456-66 [17671130.001]
  • [Cites] Cancer Immunol Immunother. 2007 Nov;56(11):1785-93 [17473921.001]
  • [Cites] Cancer Cell. 2008 Jan;13(1):23-35 [18167337.001]
  • [Cites] Oncogene. 2008 Jan 17;27(4):557-64 [17653092.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):1809-19 [18339861.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2008 Apr;28(4):665-71 [18202322.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3835-43 [18483268.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3915-23 [18483277.001]
  • [Cites] Clin Cancer Res. 2008 Jun 15;14(12):3966-74 [18559619.001]
  • [Cites] J Leukoc Biol. 2001 Aug;70(2):171-84 [11493608.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6201-12 [11507073.001]
  • [Cites] Nat Med. 2001 Oct;7(10):1118-22 [11590434.001]
  • [Cites] Cytokine Growth Factor Rev. 2002 Apr;13(2):143-54 [11900990.001]
  • [Cites] Nat Rev Immunol. 2002 Jan;2(1):46-53 [11905837.001]
  • [Cites] Blood. 2002 May 1;99(9):3179-87 [11964281.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1860-4 [12702574.001]
  • [Cites] J Clin Invest. 2004 Jun;113(11):1515-25 [15173875.001]
  • [Cites] Nat Med. 2004 Sep;10(9):909-15 [15340416.001]
  • [Cites] Clin Cancer Res. 2004 Sep 1;10(17):5907-18 [15355924.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6524-9 [15374963.001]
  • [Cites] Int J Cancer. 1992 Dec 2;52(6):881-6 [1459729.001]
  • [Cites] J Immunol. 1995 Aug 15;155(4):2077-84 [7636258.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):21-6 [8548765.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):839-49 [15516957.001]
  • [Cites] Nat Rev Drug Discov. 2004 Dec;3(12):1011-22 [15573100.001]
  • [Cites] Curr Opin Genet Dev. 2005 Feb;15(1):97-101 [15661539.001]
  • [Cites] Cancer Immunol Immunother. 2005 May;54(5):446-52 [15750831.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1761-9 [15753372.001]
  • [Cites] J Exp Med. 2005 Mar 7;201(5):779-91 [15753211.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):2078-93 [15774796.001]
  • [Cites] J Exp Med. 2005 Apr 4;201(7):1061-7 [15809351.001]
  • [Cites] J Immunol. 2005 May 1;174(9):5215-23 [15843517.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5515-25 [16061868.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8379-87 [16166316.001]
  • [Cites] Cancer Biol Ther. 2005 Mar;4(3):261-6 [15846079.001]
  • [Cites] J Immunol. 2005 Nov 1;175(9):6169-76 [16237114.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):369-80 [16286245.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11752-61 [16357188.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):214-22 [16397045.001]
  • [Cites] Curr Opin Genet Dev. 2006 Feb;16(1):30-7 [16377175.001]
  • [Cites] J Clin Invest. 2006 Jul;116(7):1935-45 [16778987.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4315-30 [16857807.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4794-803 [16914564.001]
  • (PMID = 19074893.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA066726; United States / NCI NIH HHS / CA / P01 CA066726-12; United States / NCI NIH HHS / CA / CA066726-120002; United States / NCI NIH HHS / CA / P01 CA 66726; United States / NIEHS NIH HHS / ES / ES013508-02; United States / NIEHS NIH HHS / ES / P30 ES013508; United States / NCI NIH HHS / CA / CA066726-12; United States / NIEHS NIH HHS / ES / P30 ES013508-02; United States / NCI NIH HHS / CA / P01 CA066726-120002
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Azabicyclo Compounds; 0 / Cancer Vaccines; 0 / Cytokines; 0 / Epitopes, T-Lymphocyte; 0 / Icam1 protein, mouse; 0 / Oncogene Proteins, Viral; 0 / RNA, Messenger; 0 / SM16 compound; 0 / Transforming Growth Factor beta; 126547-89-5 / Intercellular Adhesion Molecule-1; 77238-31-4 / Interferon-beta
  • [Other-IDs] NLM/ NIHMS78784; NLM/ PMC2637471
  •  go-up   go-down


26. Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, Chao Q, Jacob S, Turchin H, Gibbs L, Phillips MD, Mudali S, Iacobuzio-Donahue C, Jaffee EM, Moreno M, Pastan I, Sass PM, Nicolaides NC, Grasso L: Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun; 2007;7:20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Novel therapeutic agents that are safe and effective are needed for the treatment of pancreatic, ovarian, lung adenocarcinomas and mesotheliomas.
  • Mesothelin is a glycosyl-phosphatidyl inositol (GPI)-linked membrane protein of 40 kDa over-expressed in all pancreatic adenocarcinoma and mesothelioma, in >70% of ovarian adenocarcinoma, and in non-small cell lung and colorectal cancers.
  • We have recently developed MORAb-009, a mouse-human chimeric IgG1kappa monoclonal antibody with an affinity of 1.5 nM for human mesothelin.
  • Treatment that included MORAb-009 in combination with chemotherapy led to a marked reduction in tumor growth of mesothelin-expressing tumors in nude mice compared to chemotherapy or MORAb-009 treatment alone.
  • We have in fact initiated a Phase I clinical study enrolling patients with mesothelin-positive pancreatic, mesothelioma, non-small cell lung and ovarian cancers.
  • [MeSH-major] Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / immunology. Antibodies, Neoplasm / therapeutic use. Membrane Glycoproteins / antagonists & inhibitors. Membrane Glycoproteins / immunology. Neoplasms / drug therapy
  • [MeSH-minor] Animals. Antibody-Dependent Cell Cytotoxicity / drug effects. Antineoplastic Agents / pharmacology. Cell Adhesion / drug effects. Cell Line, Tumor. Drug Evaluation, Preclinical. Drug-Related Side Effects and Adverse Reactions. Endocytosis / drug effects. GPI-Linked Proteins. Humans. Mice. Mice, Nude

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2001 Sep;7(9):987-9 [11533692.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(8):2902-6 [10733593.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3862-8 [11751476.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):150-8 [12548160.001]
  • [Cites] Mod Pathol. 2003 Mar;16(3):192-7 [12640097.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1418-28 [14576474.001]
  • [Cites] J Biol Chem. 2004 Mar 5;279(10):9190-8 [14676194.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937-42 [15217923.001]
  • [Cites] J Exp Med. 2004 Aug 2;200(3):297-306 [15289501.001]
  • [Cites] Int J Cancer. 1992 Feb 1;50(3):373-81 [1735605.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136-40 [8552591.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):669-74 [9435250.001]
  • [Cites] Cancer J Sci Am. 1998 May-Jun;4(3):194-203 [9612602.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):243-7 [16082249.001]
  • [Cites] Cancer Biol Ther. 2005 May;4(5):548-54 [15846069.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7158s-7163s [16203816.001]
  • [Cites] Am J Clin Pathol. 2005 Dec;124(6):838-45 [16416732.001]
  • [Cites] Int J Cancer. 2006 Nov 15;119(10):2492-6 [16929494.001]
  • [Cites] Mol Cancer. 2006;5(1):50 [17067392.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1571-5 [17332303.001]
  • [Cites] J Immunol Methods. 1999 Dec 10;231(1-2):83-91 [10648929.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2862-9 [11555604.001]
  • (PMID = 18088084.001).
  • [ISSN] 1424-9634
  • [Journal-full-title] Cancer immunity
  • [ISO-abbreviation] Cancer Immun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / GPI-Linked Proteins; 0 / MORAb-009 monoclonal antibody; 0 / Membrane Glycoproteins; 0 / mesothelin
  • [Other-IDs] NLM/ PMC2935758
  •  go-up   go-down


27. Fridlender ZG, Buchlis G, Kapoor V, Cheng G, Sun J, Singhal S, Crisanti MC, Wang LC, Heitjan D, Snyder LA, Albelda SM: CCL2 blockade augments cancer immunotherapy. Cancer Res; 2010 Jan 1;70(1):109-18
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anti-murine CCL2/CCL12 monoclonal antibodies were administered in three immunotherapy models: one aimed at the human papillomavirus E7 antigen expressed by a non-small cell lung cancer (NSCLC) line, one targeted to mesothelin expressed by a mesothelioma cell line, and one using an adenovirus-expressing IFN-alpha to treat a nonimmunogenic NSCLC line.
  • We evaluated the effect of the combination treatment on tumor growth and assessed the mechanism of these changes by evaluating cytotoxic T cells, immunosuppressive cells, and the tumor microenvironment.
  • The combined treatment generated more total intratumoral CD8+ T cells that were more activated and more antitumor antigen-specific, as measured by tetramer evaluation.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Drug Discov. 2003 Oct;2(10):803-11 [14526383.001]
  • [Cites] J Immunol. 2003 Nov 15;171(10):5051-63 [14607902.001]
  • [Cites] Am J Transplant. 2004 Jan;4(1):65-78 [14678036.001]
  • [Cites] J Immunol. 2004 Jan 15;172(2):890-8 [14707060.001]
  • [Cites] Eur J Immunol. 2004 Mar;34(3):743-51 [14991604.001]
  • [Cites] Immunol Lett. 2004 Feb 15;91(2-3):239-45 [15019295.001]
  • [Cites] Semin Cancer Biol. 2004 Jun;14(3):149-54 [15246049.001]
  • [Cites] Nat Med. 2004 Sep;10(9):909-15 [15340416.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3652-6 [8170963.001]
  • [Cites] J Clin Invest. 1995 May;95(5):2391-6 [7738202.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):21-6 [8548765.001]
  • [Cites] J Exp Med. 1997 Jan 6;185(1):99-109 [8996246.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4849-54 [9354448.001]
  • [Cites] Immunol Today. 1999 Apr;20(4):158-60 [10203710.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8379-87 [16166316.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6713-21 [16166452.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3322-30 [16037386.001]
  • [Cites] Cell Immunol. 2005 Jun;235(2):122-35 [16243300.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):214-22 [16397045.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):1750-8 [16424205.001]
  • [Cites] Cancer Gene Ther. 2006 Jul;13(7):664-75 [16514422.001]
  • [Cites] Neoplasia. 2006 Jul;8(7):578-86 [16867220.001]
  • [Cites] J Clin Invest. 2006 Oct;116(10):2777-90 [17016559.001]
  • [Cites] Ann Oncol. 2007 Feb;18(2):226-32 [17116643.001]
  • [Cites] Arthritis Res Ther. 2007;9(1):R15 [17284325.001]
  • [Cites] Cancer Res. 2008 Dec 15;68(24):10247-56 [19074893.001]
  • [Cites] Cancer Immunol Immunother. 2000 May;49(2):63-70 [10823415.001]
  • [Cites] Blood. 2000 Jul 1;96(1):34-40 [10891427.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3282-9 [10955814.001]
  • [Cites] J Immunol. 2001 Jun 1;166(11):6483-90 [11359798.001]
  • [Cites] J Exp Med. 2001 Sep 17;194(6):847-53 [11560999.001]
  • [Cites] Nat Immunol. 2002 Jul;3(7):611-8 [12087419.001]
  • [Cites] Annu Rev Immunol. 2003;21:807-39 [12615893.001]
  • [Cites] Nat Rev Immunol. 2003 Aug;3(8):630-41 [12974478.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1167-74 [17476346.001]
  • [Cites] J Immunol. 2007 Sep 1;179(5):3332-41 [17709550.001]
  • [Cites] Neoplasia. 2007 Jul;9(7):556-62 [17710158.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5256-61 [17875753.001]
  • [Cites] Immunol Lett. 2007 Oct 31;113(1):19-28 [17868906.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9417-24 [17909051.001]
  • [Cites] Cancer Immunol Immunother. 2008 Jan;57(1):123-31 [17522861.001]
  • [Cites] Eur J Cancer. 2008 Jan;44(1):46-53 [17945478.001]
  • [Cites] J Immunol. 2008 Mar 1;180(5):2886-93 [18292510.001]
  • [Cites] Hum Antibodies. 2007;16(3-4):117-25 [18334747.001]
  • [Cites] Immunol Rev. 2008 Apr;222:155-61 [18364000.001]
  • [Cites] Hum Immunol. 2008 Apr-May;69(4-5):241-9 [18486758.001]
  • [Cites] Expert Opin Emerg Drugs. 2008 Jun;13(2):295-308 [18537522.001]
  • [Cites] N Engl J Med. 2008 Jun 19;358(25):2704-15 [18565863.001]
  • [Cites] J Immunol. 2008 Oct 15;181(8):5791-802 [18832739.001]
  • [ErratumIn] Cancer Res. 2010 Mar 15;70(6):2569. Crisanti, Cecilia [corrected to Crisanti, M Cecilia]
  • (PMID = 20028856.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA066726; United States / NHLBI NIH HHS / HL / T32 HL007586-18; United States / NHLBI NIH HHS / HL / T32 HL007586; United States / NCI NIH HHS / CA / P01 CA 66726; United States / NHLBI NIH HHS / HL / HL007586-18; United States / NCI NIH HHS / CA / CA066726-10A2; United States / NCI NIH HHS / CA / P01 CA066726-10A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Ccl12 protein, mouse; 0 / Ccl2 protein, mouse; 0 / Chemokine CCL2; 0 / Monocyte Chemoattractant Proteins
  • [Other-IDs] NLM/ NIHMS158692; NLM/ PMC2821565
  •  go-up   go-down


28. Capiaux GM, Budak-Alpdogan T, Alpdogan O, Bornmann W, Takebe N, Banerjee D, Maley F, Bertino JR: Protection of hematopoietic stem cells from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene. Cancer Gene Ther; 2004 Dec;11(12):767-73
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Myelosuppression is one of the major side effects of most anticancer drugs.
  • To confer myeloprotection, our laboratory generated drug-resistant mutants of select target human enzymes for gene transfer to the bone marrow.
  • In this study, we examined the sensitivity of the DHFR F/S-TS G52S fusion protein to the multitargeted antifolate, pemetrexed (LY231514, Alimta), which targets both DHFR and TS and is currently in phase III trials for the treatment of solid tumors and in combination with cisplatin has been shown to be an advance in the treatment of mesothelioma.
  • Similarly, expression of the DHFR F/S-TS G52S fusion gene in retrovirally transduced mouse marrow cells resulted in an increased survival of CFU-GM colonies when compared to cells transduced with either of the mutants alone.
  • This construct may be useful for conferring myeloprotection to patients receiving this drug.
  • [MeSH-major] Cytoprotection / genetics. Gene Expression Regulation. Genetic Therapy / methods. Glutamates / toxicity. Guanine / analogs & derivatives. Guanine / toxicity. Hematopoietic Stem Cells / drug effects. Tetrahydrofolate Dehydrogenase / genetics. Thymidylate Synthase / genetics

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PEMETREXED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15359285.001).
  • [ISSN] 0929-1903
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA59350; United States / NCI NIH HHS / CA / R01 CA-08010; United States / NCI NIH HHS / CA / R01-CA 44355
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glutamates; 0 / Recombinant Fusion Proteins; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; EC 1.5.1.3 / Tetrahydrofolate Dehydrogenase; EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down






Advertisement